西班牙VEXAS综合征队列:临床表现、治疗结局及UBA1嵌合现象的新证据
该西班牙队列对42例成年起病未确诊自身炎症性疾病患者行UBA1基因分析,30例携带致病性变异,均为男性,平均起病年龄67.5岁,以皮损、发热、肺部表现和关节炎为主要特征。糖皮质激素可改善炎症但多数患者依赖,靶向造血成分的地西他滨或异基因造血干细胞移植获阳性反应;首次在非造血组织检出UBA1嵌合。
要点
- 42例成年起病未确诊自身炎症性疾病患者中30例检出UBA1致病性变异。
- 30例均为男性,平均起病年龄67.5岁,皮损90%、发热66.7%、肺部表现66.7%、关节炎53.3%。
- 糖皮质激素改善炎症但多数患者依赖,靶向造血成分的地西他滨或异基因造血干细胞移植获阳性反应。
核心结论
- 通过基因分析,30例成年起病自身炎症性疾病患者被确诊为VEXAS综合征,其主要特征与既往报道一致。
- 首次在非造血组织检出UBA1嵌合现象,对既往骨髓限制性嵌合的概念提出质疑,并可能对该病机制有概念性影响。
研究设计与样本
- 对入组的42例成年起病未确诊自身炎症性疾病患者行Sanger测序和基于扩增子的深度测序基因分析。
- 患者数据取自病历,细胞因子用Luminex定量。
主要发现
- 42例入组患者中30例携带UBA1致病性变异,其频率与体细胞嵌合变异相符。
- 30例均为男性,起病晚(平均67.5岁;中位67.0岁),表现为皮损(90%)、发热(66.7%)、肺部表现(66.7%)和关节炎(53.3%)。
- 大细胞性贫血以及红细胞沉降率和铁蛋白升高是最相关的实验室异常。
- 糖皮质激素改善炎症表现,但多数患者出现糖皮质激素依赖。
- 靶向疾病造血成分的地西他滨或异基因造血干细胞移植获得阳性反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The vacuoles, E1-enzyme, X linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease (AID) due to postzygotic UBA1 variants. OBJECTIVES: To investigate the presence of VEXAS syndrome among patients with adult-onset undiagnosed AID. Additional studies evaluated the mosaicism distribution and the circulating cytokines. METHODS: Gene analyses were performed by both Sanger and amplicon-based deep sequencing. Patients' data were collected from their medical charts. Cytokines were quantified by Luminex. RESULTS: Genetic analyses of enrolled patients (n=42) identified 30 patients carrying UBA1 pathogenic variants, with frequencies compatible for postzygotic variants. All patients were male individuals who presented with a late-onset disease (mean 67.5 years; median 67.0 years) characterised by cutaneous lesions (90%), fever (66.7%), pulmonary manifestations (66.7%) and arthritis (53.3%). Macrocytic anaemia and increased erythrocyte sedimentation rate and ferritin were the most relevant analytical abnormalities. Glucocorticoids ameliorated the inflammatory manifestations, but most patients became glucocorticoid-dependent. Positive responses were obtained when targeting the haematopoietic component of the disease with either decitabine or allogeneic haematopoietic stem cell transplantation. Additional analyses detected the UBA1 variants in both haematopoietic and non-haematopoietic tissues. Finally, analysis of circulating cytokines did not identify inflammatory mediators of the disease. CONCLUSION: Thirty patients with adult-onset AID were definitively diagnosed with VEXAS syndrome through genetic analyses. Despite minor interindividual differences, their main characteristics were in concordance with previous reports. We detected for the first time the UBA1 mosaicism in non-haematopoietic tissue, which questions the previous concept of myeloid-restricted mosaicism and may have conceptual consequences for the disease mechanisms.
引用
- Mascaro JM, Rodriguez-Pinto I, Poza G, et al. Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism. Ann Rheum Dis. 2023. PMID: 37666646. doi:10.1136/ard-2023-224460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。